Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
HAE 
Haemonetics Corporation (HAE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/11/2025: HAE (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $78.64
1 Year Target Price $78.64
| 3 | Strong Buy |
| 5 | Buy |
| 1 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -38.79% | Avg. Invested days 48 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/11/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.59B USD | Price to earnings Ratio 16.35 | 1Y Target Price 78.64 |
Price to earnings Ratio 16.35 | 1Y Target Price 78.64 | ||
Volume (30-day avg) 10 | Beta 0.39 | 52 Weeks Range 50.68 - 94.98 | Updated Date 09/12/2025 |
52 Weeks Range 50.68 - 94.98 | Updated Date 09/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 3.27 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 12.14% | Operating Margin (TTM) 20.21% |
Management Effectiveness
Return on Assets (TTM) 6.52% | Return on Equity (TTM) 18.27% |
Valuation
Trailing PE 16.35 | Forward PE 10.98 | Enterprise Value 3508403650 | Price to Sales(TTM) 1.92 |
Enterprise Value 3508403650 | Price to Sales(TTM) 1.92 | ||
Enterprise Value to Revenue 2.61 | Enterprise Value to EBITDA 9.99 | Shares Outstanding 48177300 | Shares Floating 47598165 |
Shares Outstanding 48177300 | Shares Floating 47598165 | ||
Percent Insiders 1.15 | Percent Institutions 115.72 |
Upturn AI SWOT
Haemonetics Corporation
Company Overview
History and Background
Haemonetics Corporation was founded in 1971. It initially focused on developing automated blood processing technology. Over time, it expanded its portfolio through organic growth and acquisitions, becoming a leader in blood management solutions.
Core Business Areas
- Plasma: Provides technology and solutions for plasma collection centers.
- Blood Bank: Offers solutions for blood component processing and storage in blood banks.
- Hospital: Provides solutions for blood management in hospitals, including cell salvage and blood coagulation analysis.
Leadership and Structure
Haemonetics is led by Christopher Simon, President and CEO. The organizational structure is comprised of functional departments such as R&D, Operations, Sales, and Marketing, as well as business unit leaders for each core business area.
Top Products and Market Share
Key Offerings
- NexSys PCS: Automated plasma collection system. Market share in the plasma collection equipment market is estimated to be significant, competing with Terumo BCT and Fresenius Kabi. Revenue figures not publicly disclosed.
- Cell Saver Elite+: Autotransfusion system for intraoperative blood salvage. Competes with Medtronic's Aquamantys and LivaNova's XTRA. Revenue figures not publicly disclosed. Market share data is not easily accessible.
- TEG Hemostasis System: A point-of-care diagnostic system that provides comprehensive assessment of a patient's hemostatic function. The competitors are ROTEM by Tem International GmbH, and ClotPro by Haemoscope Corporation
Market Dynamics
Industry Overview
The blood management solutions industry is driven by factors such as the increasing demand for blood and plasma products, advancements in medical technology, and the growing prevalence of chronic diseases. The industry is competitive, with several large players and smaller specialized companies.
Positioning
Haemonetics is a well-established player in the blood management solutions market, with a strong brand reputation and a broad product portfolio. Its competitive advantages include its technological expertise, its global distribution network, and its strong customer relationships.
Total Addressable Market (TAM)
The global blood management market is expected to reach ~$15 billion by 2028. Haemonetics is positioned to capture a significant portion of this market through its diverse product offerings and strategic initiatives.
Upturn SWOT Analysis
Strengths
- Strong Brand Recognition
- Global Distribution Network
- Technological Expertise
- Diverse Product Portfolio
- Recurring Revenue Streams
Weaknesses
- Dependence on Plasma Collection Market
- Exposure to Reimbursement Changes
- Competition from Larger Companies
- Currency Fluctuations
Opportunities
- Expansion into Emerging Markets
- Development of New Products and Services
- Acquisitions of Complementary Businesses
- Growth in Cell Therapy Applications
Threats
- Intense Competition
- Technological Obsolescence
- Regulatory Changes
- Economic Downturns
Competitors and Market Share
Key Competitors
- TER (Terumo Corporation)
- FMS (Fresenius Medical Care)
- MDT (Medtronic)
Competitive Landscape
Haemonetics competes with larger and smaller companies, with its primary advantage being its specialized expertise and established customer base. Its disadvantages are a lack of scale compared to larger competitors.
Major Acquisitions
Cardiva Medical, Inc.
- Year: 2021
- Acquisition Price (USD millions): 510
- Strategic Rationale: Expanded Haemonetics' hospital portfolio and broadened its presence in interventional cardiology.
Growth Trajectory and Initiatives
Historical Growth: Haemonetics has experienced moderate growth over the past decade, driven by expansion in the plasma and hospital markets.
Future Projections: Analysts expect Haemonetics to continue growing at a moderate pace, driven by increasing demand for blood and plasma products, as well as new product introductions. Specific growth rates depend on market dynamics and execution of strategy.
Recent Initiatives: Recent initiatives include investments in R&D, acquisitions of complementary businesses, and expansion into emerging markets.
Summary
Haemonetics is a well-established player in the blood management solutions market with a diverse product portfolio and global presence. It benefits from recurring revenue streams and technological expertise, yet faces competition from larger players and exposure to reimbursement changes. Recent acquisitions and strategic initiatives position the company for continued growth in expanding markets. Maintaining technological leadership and adapting to evolving healthcare regulations are critical for sustained success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Industry Reports
- Analyst Estimates
- Company Website
- Third-Party Financial Data Providers
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Haemonetics Corporation
Exchange NYSE | Headquaters Boston, MA, United States | ||
IPO Launch date 1991-05-09 | CEO, President & Director Mr. Christopher A. Simon | ||
Sector Healthcare | Industry Medical Devices | Full time employees 3023 | Website https://www.haemonetics.com |
Full time employees 3023 | Website https://www.haemonetics.com | ||
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. It also provides treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE closure products comprising VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, clinical specialists, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.